Chilling when we want. Now Playing on JACK 3 Chill

Yester Me Yester You Yesterday

Stevie Wonder

Mix and match vaccine study in Oxford is extended to include two more jabs

PIC: Yui Mok

The Moderna and Novovax vaccines are being added to the study.

A study looking at whether the Oxford/Astrazeneca and Pfizer coronavirus vaccines can be safely mixed for the first and second doses will be expanded to include two additional jabs.

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the first two jabs to be rolled out across the UK, have announced the programme will be extended to include the Moderna and Novavax vaccines.

Led by the University of Oxford, the study will seek to recruit adults aged over 50 who have received their first vaccination in the past eight to 12 weeks.

Matthew Snape, associate professor in paediatrics and vaccinology at the University of Oxford, who is chief investigator on the trial said: “The focus of both this and the original Com-Cov study is to explore whether the multiple Covid-19 vaccines that are available can be used more flexibly, with different vaccines being used for the first and second dose.

“If we can show that these mixed schedules generate an immune response that is as good as the standard schedules, and without a significant increase in the vaccine reactions, this will potentially allow more people to complete their Covid-19 immunisation course more rapidly.

“This would also create resilience within the system in the event of a shortfall in availability of any of the vaccines in use.”

The volunteers, who will have received either the Oxford/AstraZeneca, or Pfizer/BioNTech vaccine, will be randomly allocated to receive either the same vaccine for their second dose, or a dose of the jabs produced by Moderna or Novavax.

The Moderna jab has started being rolled out across the UK, and the Novavax jab manufactured by GlaxoSmithKline (GSK) is under rolling review by the Medicines and Healthcare products Regulatory Agency (MHRA).

The six new arms of the trial will each recruit 175 candidates, adding 1,050 recruits into this programme.

The researchers will study any adverse reactions and the immune system responses to these new combinations of vaccines.

The study is designed as a so-called non-inferiority study, which means its intent is to demonstrate that mixing is not substantially worse than not mixing.

It will compare the immune system responses to the gold-standard responses reported in previous clinical trials of each vaccine.

If the study shows promising results, the MHRA and Joint Committee on Vaccination and Immunisation would formally assess the safety and efficacy of any new vaccination regimen before it is rolled out to patients.

More from Oxfordshire News

Get more from JACK 3

Someone’s greedy. Join the JACKaholics to get more access behind the scenes and the latest updates. Our emails won’t enlarge much except the size of your inbox.

Weather

  • Wed

    15°C

  • Thu

    14°C

  • Fri

    14°C

  • Sat

    14°C

  • Sun

    15°C